ACSAC
Financiado
Aza Claisen Sakurai Approach to Cyclopentylamines
"Cyclopentylamines are ubiquitous compounds within nature and many pharmaceutical products. Their synthesis can be problematic with length and unselective sequences plaguing them. We aim to overcome this shortcoming by developing...
"Cyclopentylamines are ubiquitous compounds within nature and many pharmaceutical products. Their synthesis can be problematic with length and unselective sequences plaguing them. We aim to overcome this shortcoming by developing a new approach whereby we couple two well known reactions; the Aza-Claisen (or Aza-Cope) rearrangement and the Sakurai allylation.
The expected outcomes of this research are a new method which is both rapid and selective for the synthesis of cyclopentylamines. We also intend to achieve the total synthesis of the compound (-)-Altemicidin, a highly substituted cyclopentylamine which exhibits potent antitumor and acaricidal properties. Any compounds produced will be screened against various disease states either here at Queen’s using the Centre for Cancer Research and Cell Biology or with our academic and industrial partners."
ver más
Línea de financiación: concedida
El organismo FP7 notifico la concesión del proyecto el día 2014-07-03
Presupuesto
El presupuesto total del proyecto asciende a
209K€
Líder del proyecto
THE QUEENS UNIVERSITY OF BELFAST
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
249.89K€ |
Participante